These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9412458)

  • 1. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1.
    Sternsdorf T; Jensen K; Will H
    J Cell Biol; 1997 Dec; 139(7):1621-34. PubMed ID: 9412458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular localization, expression, and structure of the nuclear dot protein 52.
    Sternsdorf T; Jensen K; Züchner D; Will H
    J Cell Biol; 1997 Jul; 138(2):435-48. PubMed ID: 9230084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins.
    Chelbi-Alix MK; de Thé H
    Oncogene; 1999 Jan; 18(4):935-41. PubMed ID: 10023669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small ubiquitin-related modifiers: A novel and independent class of autoantigens in primary biliary cirrhosis.
    Janka C; Selmi C; Gershwin ME; Will H; Sternsdorf T
    Hepatology; 2005 Mar; 41(3):609-16. PubMed ID: 15726652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small Ubiquitin-like Modifier Alters IFN Response.
    Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
    J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and functional heterogeneity of nuclear bodies.
    Bloch DB; Chiche JD; Orth D; de la Monte SM; Rosenzweig A; Bloch KD
    Mol Cell Biol; 1999 Jun; 19(6):4423-30. PubMed ID: 10330182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of SUMO-1-modified PML in nuclear body formation.
    Zhong S; Müller S; Ronchetti S; Freemont PS; Dejean A; Pandolfi PP
    Blood; 2000 May; 95(9):2748-52. PubMed ID: 10779416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia.
    Boddy MN; Howe K; Etkin LD; Solomon E; Freemont PS
    Oncogene; 1996 Sep; 13(5):971-82. PubMed ID: 8806687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies.
    Engelhardt OG; Ullrich E; Kochs G; Haller O
    Exp Cell Res; 2001 Dec; 271(2):286-95. PubMed ID: 11716541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.
    Duprez E; Saurin AJ; Desterro JM; Lallemand-Breitenbach V; Howe K; Boddy MN; Solomon E; de Thé H; Hay RT; Freemont PS
    J Cell Sci; 1999 Feb; 112 ( Pt 3)():381-93. PubMed ID: 9885291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.
    Müller S; Dejean A
    J Virol; 1999 Jun; 73(6):5137-43. PubMed ID: 10233977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML).
    Grötzinger T; Sternsdorf T; Jensen K; Will H
    Eur J Biochem; 1996 Jun; 238(2):554-60. PubMed ID: 8681971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequestration of PML and Sp100 proteins in an intranuclear viral structure during herpes simplex virus type 1 infection.
    Puvion-Dutilleul F; Venturini L; Guillemin MC; de Thé H; Puvion E
    Exp Cell Res; 1995 Dec; 221(2):448-61. PubMed ID: 7493645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1.
    Ishov AM; Sotnikov AG; Negorev D; Vladimirova OV; Neff N; Kamitani T; Yeh ET; Strauss JF; Maul GG
    J Cell Biol; 1999 Oct; 147(2):221-34. PubMed ID: 10525530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-dimensional organization of promyelocytic leukemia nuclear bodies.
    Lang M; Jegou T; Chung I; Richter K; Münch S; Udvarhelyi A; Cremer C; Hemmerich P; Engelhardt J; Hell SW; Rippe K
    J Cell Sci; 2010 Feb; 123(Pt 3):392-400. PubMed ID: 20130140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for separate ND10-binding and homo-oligomerization domains of Sp100.
    Negorev D; Ishov AM; Maul GG
    J Cell Sci; 2001 Jan; 114(Pt 1):59-68. PubMed ID: 11112690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers.
    Sternsdorf T; Jensen K; Reich B; Will H
    J Biol Chem; 1999 Apr; 274(18):12555-66. PubMed ID: 10212234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML.
    Engelhardt OG; Boutell C; Orr A; Ullrich E; Haller O; Everett RD
    Exp Cell Res; 2003 Feb; 283(1):36-50. PubMed ID: 12565818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis.
    Sternsdorf T; Guldner HH; Szostecki C; Grötzinger T; Will H
    Scand J Immunol; 1995 Aug; 42(2):257-68. PubMed ID: 7631159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification.
    Seeler JS; Marchio A; Losson R; Desterro JM; Hay RT; Chambon P; Dejean A
    Mol Cell Biol; 2001 May; 21(10):3314-24. PubMed ID: 11313457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.